Endocannabinoid System as Therapeutic Target of PTSD: A Systematic Review.
CBD
PTSD
PTSD treatment
THC
cannabidiol
endocannabinoids
nabilone
systematic review
Δ9-tetrahydrocannabinol
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
09 Mar 2021
09 Mar 2021
Historique:
received:
29
01
2021
revised:
20
02
2021
accepted:
05
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Post-Traumatic Stress Disorder (PTSD) is a complex disorder involving dysregulation of stress-related hormones and neurotransmitter systems. Research focused on the endocannabinoid system (eCBS) for anxiety and stress regulation, cognitive and emotional responses modulation and aversive memories extinction, leading to the hypothesis that it could represent a possible alternative treatment target for PTSD. In this systematic review, we summarize evidence about the efficacy and safety of medicinal cannabidiol (CBD), Δ
Identifiants
pubmed: 33803374
pii: life11030214
doi: 10.3390/life11030214
pmc: PMC8000573
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Curr Psychiatry Rep. 2015 Aug;17(8):600
pubmed: 26073362
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:27-34
pubmed: 26187374
Clin Drug Investig. 2014 Aug;34(8):587-91
pubmed: 24935052
Br J Pharmacol. 2019 May;176(10):1455-1469
pubmed: 29981240
Neuron. 2012 Oct 4;76(1):70-81
pubmed: 23040807
Mol Psychiatry. 2013 Sep;18(9):1034-40
pubmed: 23670490
Psychiatr Serv. 2014 Oct;65(10):1244-8
pubmed: 24981643
Neuropharmacology. 2013 Jan;64:389-95
pubmed: 22687521
Drug Alcohol Depend. 2016 Feb 1;159:219-26
pubmed: 26790822
Pharmaceuticals (Basel). 2017 Oct 08;10(4):
pubmed: 28991183
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 8;105:110116
pubmed: 32976951
Pharmacol Ther. 2020 Jul;211:107551
pubmed: 32311373
Schizophr Res. 2008 Jul;102(1-3):1-18
pubmed: 18514488
Pharmacol Res. 2016 Sep;111:668-678
pubmed: 27456243
BMC Psychiatry. 2020 Aug 26;20(1):420
pubmed: 32842985
Pharmacol Ther. 2017 Jul;175:133-150
pubmed: 28232276
Int J Clin Pract. 2020 Nov 28;:e13871
pubmed: 33249713
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Front Neurosci. 2018 Jul 24;12:502
pubmed: 30087591
Psychoneuroendocrinology. 2016 Apr;66:151-8
pubmed: 26821211
Endocrinology. 2004 Dec;145(12):5431-8
pubmed: 15331569
Headache. 2018 Jul;58(7):1139-1186
pubmed: 30152161
Neuropsychopharmacology. 2018 Jan;43(1):80-102
pubmed: 28745306
Eur J Pharmacol. 2018 Sep 5;834:230-239
pubmed: 30036537
Front Behav Neurosci. 2013 Aug 09;7:100
pubmed: 23950739
Mol Psychiatry. 2001 Jan;6(1):13-34
pubmed: 11244481
Neurosci Lett. 2017 May 10;649:181-185
pubmed: 27890743
Contemp Drug Probl. 2015 Mar;42(1):60-76
pubmed: 28638168
Br J Pharmacol. 2008 Jan;153(2):199-215
pubmed: 17828291
Neuropsychopharmacology. 2012 Jan;37(2):456-66
pubmed: 21918506
Curr Opin Psychol. 2017 Apr;14:78-83
pubmed: 28813324
Pain Med. 2020 Oct 1;21(10):2212-2218
pubmed: 33118602
J Altern Complement Med. 2019 Apr;25(4):392-397
pubmed: 30543451
Drug Test Anal. 2012 Jul-Aug;4(7-8):649-59
pubmed: 22736575
Curr Drug Targets. 2015;16(10):1094-106
pubmed: 25944011
Psychoneuroendocrinology. 2015 Jan;51:585-8
pubmed: 25467221
Psychol Addict Behav. 2011 Sep;25(3):554-8
pubmed: 21480682
Life Sci. 2011 Mar 14;88(11-12):504-11
pubmed: 21262236
J Clin Epidemiol. 2011 Apr;64(4):380-2
pubmed: 21185693
Eur J Psychotraumatol. 2016 Nov 08;7:31858
pubmed: 27837583
Biol Psychiatry. 2016 Apr 1;79(7):516-25
pubmed: 26698193
Am J Addict. 2015 Dec;24(8):705-12
pubmed: 26587796
J Clin Neurophysiol. 2020 Jan;37(1):28-34
pubmed: 31895187
Curr Psychiatry Rep. 2015 Apr;17(4):564
pubmed: 25749751
Curr Psychiatry Rep. 2019 Jun 26;21(7):61
pubmed: 31243637
J Dual Diagn. 2020 Jan-Mar;16(1):120-139
pubmed: 31479625
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):169-80
pubmed: 19141307
N Engl J Med. 2017 Jun 22;376(25):2459-2469
pubmed: 28636846
Am J Drug Alcohol Abuse. 2014 Jan;40(1):23-30
pubmed: 24205805
Psychopharmacology (Berl). 2013 Apr;226(4):781-92
pubmed: 23307069
Neuropsychopharmacology. 2018 May;43(6):1284-1296
pubmed: 29265107
J Clin Psychiatry. 2018 Dec 18;80(3):
pubmed: 30695292
J Obstet Gynaecol Can. 2020 Sep 30;:
pubmed: 33132057
FEBS Lett. 2006 Aug 7;580(18):4337-45
pubmed: 16844117
Neuropsychopharmacology. 2016 Jan;41(1):80-102
pubmed: 26068727
Neuropharmacology. 2012 Jan;62(1):373-84
pubmed: 21867717
Neurobiol Learn Mem. 2018 Mar;149:68-76
pubmed: 29432803
Behav Brain Res. 2013 Aug 1;250:23-7
pubmed: 23643693
J Psychoactive Drugs. 2014 Jan-Mar;46(1):73-7
pubmed: 24830188
Neuroscience. 2012 Mar 1;204:159-85
pubmed: 22173015
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:124-140
pubmed: 30946942
Prog Mol Biol Transl Sci. 2016;137:123-47
pubmed: 26810000
J Psychopharmacol. 2011 Jan;25(1):121-30
pubmed: 20829306
J Clin Pharmacol. 1981 Aug-Sep;21(S1):417S-427S
pubmed: 7028792
Medicina (Kaunas). 2019 Aug 23;55(9):
pubmed: 31450833
J Clin Psychopharmacol. 2014 Oct;34(5):559-64
pubmed: 24987795
Sleep Med Rev. 2020 Oct;53:101339
pubmed: 32603954
J Psychiatr Pract. 2004 Mar;10(2):106-18
pubmed: 15330406
CNS Neurosci Ther. 2009 Winter;15(1):84-8
pubmed: 19228182
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1420-7
pubmed: 18514375
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 8;89:361-379
pubmed: 30342071
Nature. 2002 Aug 1;418(6897):530-4
pubmed: 12152079
Int Rev Psychiatry. 2009 Apr;21(2):113-21
pubmed: 19367505
Psychopharmacology (Berl). 2020 Jun;237(6):1813-1826
pubmed: 32162103
Drug Alcohol Depend. 2014 Mar 1;136:162-5
pubmed: 24412475
J Psychoactive Drugs. 2014 Jul-Aug;46(3):171-7
pubmed: 25052875
Biol Psychiatry. 2017 Oct 1;82(7):e51-e59
pubmed: 28454621
J Psychopharmacol. 2013 Mar;27(3):312-6
pubmed: 23343597
J Basic Clin Physiol Pharmacol. 2016 May 1;27(3):193-202
pubmed: 26426887
Brain Res. 2007 Jan 5;1127(1):36-44
pubmed: 17113043
J Clin Psychiatry. 2000;61 Suppl 7:5-13
pubmed: 10795604